Member Info for Feeks

Sorry can't help you as I missed the beginning, but soon there will be a release of the recorded version

* hardly priced in at all

They are onto a good thing with not just Rezorce, but Shincell too. I will not wait to buy some more, as I consider there is a very good chance the SP will be considerably higher in 6 months. Rezorce is hard priced in at all.

You are not correct. I don't want a lower price per se. I'll take any price POST -funding!

I see you invest in WSG which must make you a very optimistic investor! I was an investor in that company for a number of years. It was full of empty promises and so I am amazed anyone is still investing in it. AIM is full of tripe. APTA is quite possibly just another basket case. It is ABSOLUTELY HIGH RISK.

To be 100% clear. We are NOT looking to raise funding. It's too soon to know if things will line up or not. We do NOT want any unnecessary dilution. As you will aware, having a shored up balance sheet in case of cash delays is safer and less controversial at a higher SP."

Fine, but I've seen that before and then a 'prudent' raise, and following that the company went bust! Saietta....

To me, the above statement is entirely consistent with a raise if the speculators propel the share p;rice higher, so I won't be back in quite yet. July is not far away and any raise would be sooner than that, if the money is required. So, I expect the SP here will be volatile for a while which reflects the underlying existential risk unless and until income related news is forthcoming. That's just me being sensible, so DYOR!

I thought the "top pharma" rns was overly- rampy. Placing coming in my humble view!

Dr Tolley might be right but I take nothing for granted on AIM any more.

Sadly, "we don't need cash" does not preclude a fund raise.

Friday is often FOMO day, which tends to reverse pretty quickly on a 'hope' share, once short term good news does not arrive

To be 100% clear. We are NOT looking to raise funding. It's too soon to know if things will line up or not. We do NOT want any unnecessary dilution. As you will aware, having a shored up balance sheet in case of cash delays is safer and less controversial at a higher SP.

Who is saying that...? Is it management or just some random punter on Twitter?

Ronan held a number of other executive roles in Coats, which he joined in 1995, including Chief Transformation Officer, Regional CEO EMEA & Americas, Regional CEO South East Asia and Managing Director in several regions, including Europe and North Africa. Ronan has a Bachelor's degree in Information Management and Economics from Queen's University, Belfast and has completed an international Executive Business Programme with INSEAD in France and Singapore.

This announcement includes the information required by Listing Rules 9.6.11 to 9.6.13, and there is no information to report under Listing Rule 9.6.13R (2) - (6) inclusive.

26 March 2024 - Further to its announcement of 7 November 2023, Zotefoams (LSE: ZTF), a world leader in cellular materials technology, announces the appointment of Ronan Cox as Group CEO Designate. Ronan will join the Company on 2 April 2024 and will be appointed to the Board as an Executive Director and succeed David Stirling as Group CEO at the conclusion of the 2024 AGM, due to be held on 22 May 2024. Following his stepping down from the Board, David will remain to ensure a smooth transition until 31 October 2024.

Ronan has extensive international leadership experience, most recently as President of Performance Materials at Coats Group plc, the FTSE 250 world's leading industrial thread and footwear components manufacturer.

Commenting on the changes, Dr Lynn Drummond, Chair of the Company, said: "Under David's outstanding leadership, and following significant investment over the last decade, the Group has extended from a single site in the UK to include operations in Europe, North America and Asia. This footprint, together with Zotefoams' operational and commercial teams, provide both the capacity and capability to support continued profitable growth from the Group's core AZOTE® Polyolefin Foams and HPP foams businesses. The Group continues to progress the development and commercialisation of its unique recyclable barrier packaging technology, ReZorce® Circular Packaging.

With a strong and dedicated leadership team in place to support him, I am delighted to welcome Ronan to Zotefoams. Ronan brings a wealth of experience and I am confident he will make a significant contribution to the Group. I very much look forward to working with him."

David Stirling, Group CEO, said: "Leading Zotefoams for the past 24 years has been the greatest privilege of my professional life. I am proud of the role that my team has played in the Group's success and know that they will fully support Ronan in his transition to the role."

Ronan Cox, Group CEO Designate, commented: "Zotefoams is a business with a long history of sustainability and growth. I am honoured and excited to have the opportunity to lead a company with a strong heritage and build on David's significant achievements."

Ronan Cox Biographical Notes

Ronan is an accomplished executive leader with extensive experience in driving business transformation and growth. Most recently, he served as interim CEO for Lontra, a green technology company delivering ground-breaking air compressor designs, and President, Performance Materials for Coats Group plc, a world leader in thread and component manufacturing for apparel and footwear and textile based performance materials for industries ranging from personal protection to automotive and telecoms. Ronan also built and led the innovation teams across the Coats group with a focus on the transition to sustainable and circular product solutions. Ronan held a number of other executive roles in Coats, which he joined in 1995, including Chief T

To check on a re-watch:

1bn cartons = close to current market value of ZTF. 2bn cartons = close to 1% share of market for cartons. Customers for 1bn already lined up ready to go. Sounds very good IF it works.

.".it does not require any Capex by the end user (packager) being totally interchangeable with existing machinery."

Looks good but still slightly wary because I have heard that line before - manufacturing process changes are rarely so cheap and simple to implement ..

Quite rigjt!

Tax on beer and ciggies is fundamentally designed to raise revenue not kill sales which lead to decreased rax revenues. If that's what the Government did want (to limit use) they would ban it altogether. We know the NHS is keen on vaping as it is less costly than health problems with traditional combustible tabacco products

I've had my seat belt on for the past 3 weeks, but it has has not helped my investment in this car crash of a company.

The market knows best!

Aside from the (good...!?) trading update is there a second RNS....?

Why marked down....?

Https://www.recoup.org/membership/our-members/

Funding is not the problem per se. It is funding for the type of rapid scale up that they would wish for that is the problem. The company is reaching for big targets when it could have set more modest goals - and if it does not getting the right backing those more limited goals are what it will be left with.

It will get funding for scale up - there are long term investors who want to see it. But the price of that expansion is horrific and the damage most acute for existing private investors.

Not great. Thank you for asking. It's amateurish to load up too much / become overexposed on smallcaps- and not taking the pain by selling when it seems right to sell. Think I will keep well away from companies needing factories/ capital intensive investments. Or the stock market.